Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders

Animal models of neurodegenerative and inflammatory diseases, have greatly contributed to our understanding of human disorders such as multiple sclerosis (MS). These models play a key role in drug development and have led to novel therapeutic approaches to treat human diseases. Nevertheless, some studies showing efficacy of therapies in animal models have not translated well to the clinic. In part, this disparity can be explained by differences in the biology of animals and humans. Another contributing factor is the quality of execution and reporting of studies, which is the responsibility of the authors. However, the acceptance of these papers depends on the quality of refereeing and editorial proficiency. When reporting animal studies, it is recommended that manuscripts conform to the principals of the Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines (Kilkenny et al., 2010). This provides a list of 20 guidelines that should be employed in order to make papers consistent as well as transparent. However, conformation to the ARRIVE guidelines requires significantly more information than current publications often report. We have thus refined the ARRIVE guidelines, incorporated the 3Rs (Reduction, Refinement and Replacement) principals, and specifically adapted them to the reporting of animal models of multiple sclerosis (MS) and related disorders. As an example we have used experimental autoimmune encephalomyelitis (EAE), the most widely used model of MS, since many EAE studies lack evidence of adoption of indicators of quality (Kilkenny et al., 2009; Baker and Amor, 2010; Vesterinen et al., 2010). The guide, reported here, is intended to act as a checklist to aid both authors and referees of manuscripts, just as the Consolidated Standards of Reporting Trials (CONSORT) guidelines are a compulsory part of reporting clinical trials. Our aim is to improve the conclusions drawn from EAE studies and thus aid better translation to the clinical and treatment of MS. It is thus recommended that this checklist be adhered to for both authors and referees of papers submitted to all relevant journals including the journal Multiple Sclerosis and Related Disorders. (C) 2012 Elsevier B.V. All rights reserved.